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Brain tumorsAbstract Purpose: Our aim is to describe the spectrum of proton-MR spectroscopy in malignant
focal brain lesions and to detect grade of malignancy using MRS tumor biomarkers.
Materials and methods: 87 patients (63 males and 24 females) with focal brain lesion(s) are included
in this study. All had a brain tumor recently diagnosed by MRI and had received no previous treat-
ment. They were referred to MRS examination before surgical biopsy and/or resection or radiotherapy.
Results: In malignant brain tumors, average Cho/NAA ratio was 3.3 ± 0.22, Cho/Cr ratio was
2.95 ± 0.21, MI/NAA ratio was 1.5 ± 0.12, MI/Cr was 0.53 ± 0.11 with lower MI levels and
higher choline levels in more malignant tumours, lipid/lactate peak was detected in brain metastasis
and high grade malignant brain tumors.
Conclusion: Higher Cho/NAA, Cho/Cr and MI/NAA ratios with lower MI/Cr, and high lipid/
lactate peak, were most likely to be in high grade malignant brain tumors.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.1. Introduction
Magnetic resonance imaging (MRI) is considered to be the
gold standard for preoperative diagnosis, local staging and
post-therapeutic monitoring for brain tumors (1–3). In many
instances, reliable differentiation of high-grade from low-grade
tumors is difﬁcult with conventional MRI. Proton magneticresonance spectroscopy [H-MRS] (4–6) is becoming an accu-
rate non-invasive complement to MRI for initial diagnosis of
brain masses, to solve diagnostic problems since it provides
useful chemical information about metabolites for characteriz-
ing brain tumours (1–2), to differentiate low and high grade
tumours, discriminate the metastases from primary brain
tumours and abscesses (7–9).
The aim of this study was to provide objective data on the
clinical utility of MRS in differential diagnosis of malignant
brain tumours, to provide some quantitative guidelines for dis-
tinguishing low-grade from high-grade malignant neoplasms
by the use of different metabolic ratios such as Cho/NAA,
Cho/Cr, MI/NAA and MI/Cr.
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87 patients (63 males and 24 females) were prospectively
recruited for this study during a period from May 2012 to Jan-
uary 2014, ranging in age from 9–73 years (mean
39.4 ± 7.8 years). All had brain focal lesion(s) diagnosed by
MRI, all MRS results were compared with histopathology cor-
relation. This study was approved by the faculty ethics com-
mittee and informed written consent was obtained from all
patients.
3. Methods
This study was performed on a 1.5-T MR scanner (Gyroscan
Entera, Philips medical systems) using standard imaging head
coil. Images were acquired with the patient on supine position
with a pillow placed to support the head to minimize the
patient’s movement. The procedure was explained carefully
to the patients. They were asked to relax and stay still during
the examination.
Axial, sagittal and coronal planes of the brain were done in
T2 WI:TE = 100, TR= 3658. Then, MRS was done in long
TE = 288, short TE = 31 and intermediate TE = 144 with
TR = 2000 and spectral bw = 1000.
Single voxel MRS was performed, volumes of interest for
MRS were placed inside lesions. Central necrotic areas of the
lesions, ﬂuid-ﬁlled structures and fat tissue in the skull bones
were avoided when possible. Localized shimming, phase cor-
rection and water suppression were performed before acquisi-
tion of the spectra. Spectra were also obtained from the
normal tissue of the contralateral hemisphere if it was not
affected by suspicious lesion.
The pulse sequence used for MRS was point resolved single
volume spectroscopy (PRESS) with repetition time (TR)
1500 ms and echo time (TE) 35 ms. Voxel size in most cases
ranged from 1 · 1 · 1 cm to 1.5 · 1.5 · 1.5 cm. Matrix size
was 192 · 256 and ﬁeld of view was 160 · 160 · 15 mm.
Data were recorded for peaks and were used to calculate
the ratios Cho/NAA, Cho/Cr, MI/Cr and MI/NAA peak
which were analysed and compared with histopathologic
diagnosis.
Quantitative analysis of spectra was done for choline (at
3.2 ppm), myoinositol (at 3.5 ppm), creatine (at 3 ppm), N
acetylaspartate (at 2 ppm), lipid (at 1–1.4 ppm) and lactate
(at 1.3 ppm) (6). Metabolite resonance intensities were deter-
mined from ﬁtting peak areas. When metabolite resonance
intensities were markedly decreased and not determined auto-Table 1 Histopathology of 87 cases of brain tumours included
in this study.
Malignant neoplastic lesions No of cases (total 87 cases)
Low grade gliomas (grade I and II) 16
Anaplastic astrocytomas (grade III) 14
Gliomatosis cerebri (grade III and IV) 5
Glioblastomas multiforme (grade IV) 17
Supratentorial PNET 8
Medulloblastoma 8
Lymphoma 8
Metastasis 11matically (void signal), the signal intensities were estimated
manually using the graded scale on the monitor or on the ﬁlm.
These values were then placed into the different obtained
ratios. Long (288 ms), intermediate and short TE (144 and
35 ms) respectively were used to obtain Cho/NAA, Cho/Cr
ratios, and to determine the presence of Lac, while short TE
was mainly used for MI/NAA, MI/Cr ratio and Lip/lactate
peak.
MRS data were analysed and compared with the histopath-
ologic diagnosis for all cases of brain tumours. The histopath-
ologic grade was obtained after stereotactic or open surgery.
4. Results
87 patients (63 males and 24 females), age ranging from 9 to
73 years with a mean age 39.4 ± 7.8 were included in this
study. All had brain focal lesion(s) diagnosed by MRI, tumour
localizations were right or left frontal, parietal, frontoparietal,
temporal, temporooccipital, interventricular, cerebellar or cor-
pus callosum. In this study averge ratio of metabolite in total
malignant focal brain neoplastic lesions is Cho/NAA ratio was
3.32 ± 0.22, Cho/Cr ratios 2.95 ± 0.21, MI/Cr 0.53 ± 0.13,
and MI/NAA 1.51 ± 0.12 (Table 3). The tumours with regard
to MRI results were high grade glial tm (grade 4) (17 cases),
moderate glial tm (grade 3–4) (19 cases), low grade glial tm
(grade 1–2) (16 cases), PNET (4 cases of pineoblastomas, 8
cases of medulloblastoma and 4 other cases of supratentorial
PNET), lymphomas (8 cases), and metastasis (11 cases). All
patients underwent biopsy. The histopathologic conﬁrmations
were low grade astrocytoma, anaplastic astrocytoma, glioblas-
toma multiforme, gliomatosis cerebri, metastasis, PNET and
lymphoma (Table 1). Spectra from the contralateral brain or
from the healthy volunteers revealed a consistent pattern of
the four major peaks of NAA, Cr, Cho and MI, no lactate
or lipid resonances were visible.
According to H-MRS, we had 16 low-grade (grade 1–2) gli-
omas (Fig. 3), all low grade gliomas showed increased Cho and
reduced NAA resonances, with an average Cho/NAA ratio;
2.1 ± 0.31 (Table 2). Increased Cho and moderately decreased
Cr, with an average Cho/Cr ratio 1.85 ± 0.8. MI/Cr
0.96 ± 0.4, and MI/NAA 1.13 ± 0.2.
We had 19 gliomas (grade 2–3, 14 anaplastic astrocytoma
and 5 gliomatosis cerebri) with respect to S-MRS results, they
showed increased Cho and reduced NAA resonances, with an
average Cho/NAA ratio; 3.2 ± 0.02, Cho/Cr 2.8 ± 0.09, MI/
Cr 0.45 ± 0.8, and MI/NAA 1.51 ± 0.3 (Table 2).
In this study there were 17 glioblastoma multiforme (GBM)
cases (grade 4 and more). Ratios of Cho/NAA–Cho/Cr are the
highest in the GBM group, and at same time the highest cho-
line is observed in this group. Cho/NAA was 5.1 ± 1.13 and
Cho/Cr was 4.8 ± 1.31, in 12 of 17 cases, MI/Cr was
0.29 ± 0.2, MI/NAA was 2.1 ± 0.2, in 5 of 17 cases of
GBM, MI level was zero, no MI/Cr, or MI/NAA was detected
in these ﬁve cases.
We have 11 Brain metastasis cases in this study, they
showed increased Cho and highly reduced NAA resonances,
as Cho/NAA ratio was 2.9 ± 0.21, increased Cho and
decreased Cr, as Cho/Cr ratio was 2.3 ± 0.11, (MI/Cr
0.45 ± 0.2 MI/NAA 1.24 ± 0.3).
In all GMB cases, metastasis (10 of 11), 15 of 19 glial
tumours grade 2–3, 13 of 16 PNET we had highly elevated
Fig. 1 (A–C) Thirty -three years old patient with a pineoblastoma (A) MRI Axial T2 FLAIR of the brain revealed an intraventricular
well deﬁned hyperintense lesion, (B) and (C) MRS at long and short TR showed: high Cho/NAA, Cho/Cr, MI/CR was = 0.39, MI/NAA
1 84, raised lipid/lactate peak.
Table 2 MR spectroscopy mean value and standard deviation of different metabolites in different malignant brain focal neoplastic
lesions.
Neoplastic lesions Mean Cho/NAA Mean Cho/Cr Mean MI/NAA Mean MI/CR lip/lac peak MI level
Low grade gliomas (grade
I–II)
2.11 ± 0.31 1.85 ± 0.8 1.13 ± 0.2 0.96 ± 0.4 – Moderate to high
Anaplastic astrocytomas and
gliomatosis cerebri (grade III
and IV)
3.23 ± 0.02 2.81 ± 0.09 1.51 ± 0.3 0.45 ± 0.2 15 of 19 Low
Glioblastoma multiforme
(grade IV)
5.12 ± 1.13 4.83 ± 1.31 2.19 ± 0.2 0.29 ± 0.2 17 Absent to very low
PNET 4.63 ± 1.12 3.37 ± 0.8 1.84 ± 0.5 0.39 ± 0.3 13 of 16 Very low
Lymphoma 2.11 ± 0.12 2.62 ± 0.8 1.32 ± 0.4 0.64 ± 0.5 – Moderate
Metastasis 2.91 ± 0.21 2.32 ± 0.11 1.24 ± 0.3 0.45 ± 0.2 10 of 11 Moderate
Value of MRS tumour biomarkers in preoperative prediction of grades of malignancy 1203lactate and lipid peaks. In low grade glial tumours, we have no
lactate peak detected.
In cases of lymphoma in this study (Fig. 6), mean Cho/NAA
ratio 2.1 ± 0.12, Cho/Cr ratio 2.6 ± 0.8, MI/Cr 0.64 ± 0.5
MI/NAA 1.32 ± 0.4.Fig. 2 (A–C) Fourty-ﬁve years old patient with a glioblastoma mult
right frontal hyperintense lesion with heterogenous contrast enhanceme
short TR showed high Cho/NAA, high Cho/CR, no Ml is detected, hIn cases of PNET in this study we have eight cases of supra-
tentorial PNET, four of eight cases are pineoblastomas and
eight cases of medulloblastomas, average Cho/NAA ratio
4.6 ± 1.1, increased Cho and decreased Cr, as Cho/Cr ratio
3.3 ± 0.8, MI/Cr 0.39 ± 0.3 MI/NAA 1.8 ± 0.5.iforme: (A) MRI Axial post contrast T1 WI of the brain showed:
nt and surrounding vasogenic oedema, (B) and (C) MRS long and
igh lipid/lactate peak.
1204 R.O. Kaddah, M.E. KhalilCho level varies from very high in GBM to moderate in low
grade gliomas. MI level varies from high in low grade gliomas
to low in GBM cases.
5. Discussion
Contrast-enhanced MRI is not always sufﬁcient for differenti-
ation between low and high grade malignant tumors, H-MRS
has the potential for accurate diagnosis without surgical tissue
sampling. It helps to identify the tumour type and grade (10–
12).
There was a general agreement in previous studies that Cho
was the best index for grading cerebral gliomas and its peak
obviously increases from low-grade to GBM groups (12,13).
Most of the authors used Cho/NAA–Cho/Cr ratios as valu-
able tools in determining the malignancy of cranial neoplasmsFig. 3 (A–C) Fifty-three years old patient with a low grade glioma
showed right temporal low grade glioma with mass effect, (B) and (C
Cho/NAA, MI/CR 0.96, MI/NAA 0.95.
Fig. 4 (A–C) Thirty-ﬁve years old patient with a high grade glioma
brain showed: right high parietal hypertense lesion with extending vaso
Cho/NAA, high Cho/CR, MI/CR = 0.4, MI/NAA 1.6, high lipid/lac(14,15). In the former studies, both ratios increased from
low-grade to high-grade gliomas, in metastases and primitive
neuroectodermal tumours (PNET) (14,15). In our cases of high
grade gliomas Cho peak was extremely high and gradually
increases from low to high grade of malignancy Cho/NAA
was from 2.11–5.12, Cho/Cr ratios range from a low grade
to high grade of 1.8 – 4.8, MI/Cr 0.29 – 0.9, and MI/NAA
1.1 – 2.1.
The second best discriminator between low-grade glial
tumours and malignant gliomas was the amount of lipids
and lipid lactate peak as it is present in all GBM and 15 of
19 grade 2–3 gliomas and absent in low grade gliomas.
MI increases in low-grade glial tumours as it is the marker
of astrogliosis (6,13), but in higher grade gliomas, and in
PNET, its peak sharply declines (14,15).
The level of MI may have important implications in the
presurgical grading of brain tumours derived by HMRS (16).(Astrocytoma grade II), (A) MRI Axial T2 FLAIR of the brain
) MRS at long and short TR revealed; mild elevated Cho/NAA,
(Anaplastic astrocytoma grade III). (A) MRI Axial T2 WI of the
genic oedema. (B) and (C) MRS at long and short IR showed high
tate peak.
Value of MRS tumour biomarkers in preoperative prediction of grades of malignancy 1205Castillo et al., 2000 (16) stated the following; the higher the
value of MI/Cr which approximately equals to (0.82 ± 0.25),
the diagnosis is more likely of low-grade astrocytoma, while
when MI/Cr equals 0.49 ± 0.07, intermediate glial neoplasm
is suggested. With lower values of MI/Cr which equal
0.33 ± 0.16, the diagnosis of anaplastic astrocytoma is
raised. For GBM, MI/Cr equals 0.15 ± 0.12. In general,
higher grade neoplasms correlated with MI/Cr ratio of less
than 0.5 (17).
Our cases showed lower MI/Cr in higher-grade astrocyto-
mas (anaplastic and GBM) (Figs. 2 and 4) and higher MI/Cr
in low-grade astrocytomas (Fig. 3). A higher-level MI/Cr was
related to a lower-level Cho/Cr; that is, the highest Cho/Cr
was seen in anaplastic tumours and GBMs, whereas the low-
est was seen in low-grade astrocytomas. This ﬁnding coincideFig. 5 (A–C) Fifty-seven years old patient with a brain metastasis.
enhancing intra axial mass lesion surrounded by extensive oedema sug
Ml/CR 0.41, MI/NAA 1.1. There is a high lipid/lactate peak.
Fig. 6 (A–C) Thirty-eight years old patient with a brain lymphoma
altered MR signal intensities in the midbrain and left thalamus, elici
Cho/NAA, Cho/Cr, MI/Cr 0.52, MI/NAA 0.95.with previous reports that give similar observation between
different grades of malignant brain tumours and showed that
higher [MI]/[Cr] is suggestive of lower grade gliomas in
adults (16). This may be due to the lack of activation of
phosphatidylinositol metabolism resulting in the accumula-
tion of MI (18) but disagreed with an article by Kim (19),
who mentioned that MI/Cr ratio tended to increase with
grade of malignancy, MI/Cr ratio being 0.86 ± 0.19,
1.23 ± 0.37, 1.15 ± 0.52 for grade II, grade III, and grade
IV tumours, respectively (19).
In our study our results are nearly within the same range in
all cases of gliomas except in glioblastoma cases where MI
level is 0 in 5 of 17 cases (Fig. 2), and in addition a lower rate
0.39 ± 0.3 is detected in PNET tumours (Fig. 8) and metasta-
sis 0.45 ± 0.2 (Fig. 5).(A) MRI Axial T2 WI of the brain showed right temporoparietal
gestive of metastatic. (B) and (C) High Cho/NAA, Cho/Cr ratio,
showed (A) MRI Axial T2 FLAIR of the brain showed areas of
ting high signal in FLAIR WI, (B) and (C). MRS ﬁndings: high
1206 R.O. Kaddah, M.E. KhalilBesides high-grade gliomas, metastases were also shown to
have increased Cho and signiﬁcantly reduced NAA and Cr
(20). We also had similar results in our cases (Fig. 5).
One characteristic that may be used to distinguish metasta-
sis from astrocytoma is the sharp margin of metastatic lesions,
with no spectroscopic abnormality in the immediately adjacent
tissue. In contrast, gliomas usually show spectroscopic abnor-
malities extending beyond the enhancing margin of tumor and
show a depression of NAA and increase in the choline reso-
nance (21,22).
We agree with the study (23) who mentioned that 77% of
cases of metastasis show dominant lipid/lactate peak. In our
study, metastatic lesions showed increased Cho levels withTable 3 Average ratio of different metabolites in total malignant b
Average metabolite ratio in diﬀerent malignant brain tumours Mean
3.32 ±
Fig. 7 (A and B) Fifty-three years old patient with a gliomatosis c
partially solid partially cystic right parieto-occipital SOL, MRS showe
0.45, MI/NAA 1.34, high lipid/lactate peak.
Fig. 8 (A–C) Forty-three years old patient with a supratentorial PNE
high parietal parafalcine SOL eliciting hypertense signal in T2 Wl. (B a
0.29, MI/NAA 1.65, high lipid/lactate peak.diminution in the MI/Cr values, with high MI/NAA ratios,
and the presence of lipid lactate peak in 10 of 11 (90%) cases.
It was stated that PNETs were characterized by high Cho
resonances and low alanine, N-acetyl containing compounds
(NACC), Cr, and lipid resonances (9). Pineoblastomas usually
have low minimum apparent diffusion coefﬁcient (minADC)
and restricted diffusion on diffusion-weighted imaging
(DWI) and MR spectroscopy, there is elevated choline,
decreased N-acetylaspartate (NAA), as well as slightly elevated
glutamate and taurine peak (24), in this study cases of pineo-
blastoma showed increased Cho, high increase in Cho/NAA,
Cho/Cr, and MI/Cr was 0.39, MI level was low (Fig. 1). Thir-
teen of sixteen cases of supratentorial PNET showed elevatedrain focal neoplastic lesions.
Cho/NAA Mean Cho/Cr Mean MI/NAA Mean MI/CR
0.22 2.95 ± 0.21 1.51 ± 0.12 0.53 ± 0.13
erebri: (A) MRI Axial post contrast T1 WI of the brain showed
d elevation of Cho peak, high Cho/Naa and Cho/Cr ratio, MI/Cr
T; (A) Axial MRI T2 WI of the brain showed; a well deﬁned right
nd C) MRS ﬁndings: markedly elevated choline peak, MI/Cr 0.39,
Value of MRS tumour biomarkers in preoperative prediction of grades of malignancy 1207lipid/lactate peak, increase in Cho/NAA, Cho/Cr, and MI/Cr
was 0.39 (Table 2, Fig. 8).
The most common ﬁnding is the decreased level of N-acetyl
aspartate (NAA) (25). Our cases showed high choline peaks
and MI/Cr = 0.45 and MI/NAA= 1.51 (Fig. 7).
Smith et al. (17) stated that lymphomas show reduction in
NAA, and high Cho, similar to astrocytomas. Lymphoma may
also show inﬁltration of adjacent brain, and may be
indistinguishable from astrocytoma. Lymphoma shows a sig-
niﬁcant increase in lipids, we agree with the authors because
our cases of cerebral lymphoma showed elevated Cho peak
with signiﬁcantly high Cho/NAA ratios, but no increase in
the level of lipids. MI/Cr mean value was 0.64.
S-MRS has 97% sensitivity and 87.9% speciﬁcity in deter-
mining the types of brain tumours. These values are really
quite satisfactory and makes H-MRS, non-invasive technique,
a safe trustable diagnostic modality in grading the malignancy
of all brain neoplasms (20).
Changes in Cr and NAA peaks were less helpful in analys-
ing the potential malignancy of cerebral tumours (26,27).
Based on our results it can be concluded that Ch/Cr ratio
equal to or greater than 1.8 and Cho/NAA ratios equal to
or greater than 2.1 predicted malignancy, and higher than
2.9 indicated high grade malignant tumours. MI/NAA ranges
from 1.1 in low grade to 2.1 in high grade malignant tumours,
MI/Cr ranges from 0.29 in high grade to 0.96 in low grade.
Further studies are recommended with special emphasis on
the controversy point of the level and ratio of MI/Cr.
The limitation of our study is that the single voxel MRS
value is limited in both resolution and anatomical coverage,
the possibility of sampling errors in tumors of heterogeneous
appearance cannot be excluded.
6. Conclusion
H-MRS is a non-invasive tool for detecting the presence of
cancerous tissue in the brain through its metabolic activity
using tumour biomarker for pre-operative grading of malig-
nant tumours, for categorization of all brain space occupying
lesions, it plays a critical role in pre-operative or preinterven-
tional differential diagnosis of cerebral mass lesions.
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